Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,659 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gonadal Dysfunction Clear all
Completed Phase 1 Interventional

Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer

NCT00004032
View directory record Official record
Conditions
Recurrent Ovarian Epithelial Cancer
Interventions
ALVAC-hB7.1, recombinant interferon gamma, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 9, 2026, 2:42 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

NCT00929006
View directory record Official record
Conditions
Puberty, Hyperandrogenism
Interventions
Micronized progesterone suspension, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)

NCT00151411
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Placebo, Lifestyle Intervention
Drug · Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years to 39 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Sep 9, 2026, 2:42 PM EDT
Recruiting No phase listed Observational

Avera Cancer Sequencing and Analytics Protocol (ASAP)

NCT05142033
View directory record Official record
Conditions
Cancer, Cancer Diagnosis, Early Detection of Cancer, Breast Cancer, Lung Cancer, Colon Cancer, GI Cancer, Gynecologic Cancer, Ovarian Cancer, Endometrial Cancer, CNS Cancer, Hematologic Cancer
Interventions
Not listed
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
25,000 participants
Timeline
2021 – 2026
U.S. locations
6
States / cities
Marshall, Minnesota • Aberdeen, South Dakota • Mitchell, South Dakota + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

NCT00114114
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Testosterone, Goserelin acetate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 75 Years · Male only
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Interactive Perioperative Teaching Platform (IPTP)

NCT03677453
View directory record Official record
Conditions
Tonsillar Hypertrophy, Adenoid Hypertrophy, Cryptorchidism, Hypospadias, Hydrocele
Interventions
Interactive Perioperative Teaching Platform
Other
Lead sponsor
Vidya Raman
Other
Eligibility
Up to 18 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 9, 2026, 2:42 PM EDT
Not listed No phase listed Observational

Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer

NCT03691012
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Circulating tumour DNA testing
Diagnostic Test
Lead sponsor
Walter and Eliza Hall Institute of Medical Research
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 9, 2026, 2:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

NCT04520139
View directory record Official record
Conditions
Ovarian Cancer, Cognitive Impairment
Interventions
N-Acetyl-Cysteine, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 9, 2026, 2:42 PM EDT
Terminated Phase 1 Interventional

Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome

NCT00970541
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Insulin Resistance
Interventions
Cinnamon Supplementation, Placebo (wheat flour)
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Hormone Replacement in Young Women With Premature Ovarian Failure

NCT00001951
View directory record Official record
Conditions
Healthy, Osteoporosis, Premature Ovarian Failure
Interventions
TMTDS
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 32 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2007 · Synced Sep 9, 2026, 2:42 PM EDT
Terminated Phase 1 Interventional

A Phase 1 Study of [225Ac]-FPI-1434 Injection

NCT03746431
View directory record Official record
Conditions
Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma
Interventions
[111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion, [225Ac]-FPI-1434 Injection single-dose
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer

NCT01442051
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Acute Normovolemic Hemodilution
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 69 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

NCT00620295
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
bortezomib, gemcitabine hydrochloride
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
70 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

NCT02606305
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab soravtansine, Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Reno, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 9, 2026, 2:42 PM EDT
Completed No phase listed Observational

Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer

NCT01096394
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00079222
View directory record Official record
Conditions
Cancer
Interventions
itraconazole, voriconazole
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 9, 2026, 2:42 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer

NCT06665945
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Platelet RNA expression
Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
21 Years and older · Female only
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Phase 1Phase 2 Interventional

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

NCT00217529
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
pegfilgrastim, carboplatin, docetaxel, erlotinib hydrochloride
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Sep 9, 2026, 2:42 PM EDT
Recruiting No phase listed Observational

Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors

NCT05611307
View directory record Official record
Conditions
Testicular Cancer, Survivorship, ASCVD, Coronary Artery Disease, Lipid Disorder, Hypogonadism, Male, Cisplatin Adverse Reaction, Bone Marrow Transplant Complications
Interventions
Lipid profile, Coronary artery assessment, Hormone levels for hypogonadism
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

NCT02610075
View directory record Official record
Conditions
Locally Advanced Solid Tumours, Metastatic Solid Tumours, Ovarian Cancer
Interventions
AZD1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Opioid Use, Storage, and Disposal Among Pediatric Patients After Surgery

NCT03575377
View directory record Official record
Conditions
Tonsillitis, Sleep Disordered Breathing, Hernia, Hydrocele, Hypospadias, Undescended Testicle, Circumcision
Interventions
Disposal Aid
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 17 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Mood and Nutrition Interventions in Polycystic Ovary Syndrome

NCT01899001
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
Cognitive Behavioral Therapy, Nutrition Counseling
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

NCT00132067
View directory record Official record
Conditions
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
vorinostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 9, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT01767675
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer
Interventions
Secondary Cytoreductive Surgery, Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC), platinum-based systemic chemotherapy postoperatively
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
11
States / cities
Hartford, Connecticut • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 9, 2026, 2:42 PM EDT